TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01106729

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cyanidin 3 glucoside
Description: Ingestion of 500mg of Cyanidin 3 glucoside (a naturally occurring plant pigment)
Study: NCT01594502

Intervention type: DRUG
Intervention: Dutasteride
Description: 0.5 mg daily

Intervention type: DRUG
Intervention: Dutasteride
Description: 0.5 mg daily

Intervention type: DRUG
Intervention: Dutasteride
Description: 0.5 mg daily

Intervention type: DRUG
Intervention: Placebo
Description: Placebo Comparator

Intervention type: DRUG
Intervention: Placebo
Description: Placebo Comparator

Intervention type: DRUG
Intervention: Placebo
Description: Placebo Comparator
Study: NCT03061344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DVIU treated with liquid buccal mucosal graft
Description: DVIU treated with liquid buccal mucosal graft; internal urethrotomy for urethral stricture followed by injection of morcellated buccal mucosal graft mixed with fibrin glue (Tisseel, Baxter)
Study: NCT01744691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.
Study: NCT00631475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: For patients who were administered Bosentan during BUILD 3 (NCT00391443):~continue on same dose~For patients who were administered placebo during BUILD 3 (NCT00391443):~Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs \< 90 lbs.)
Study: NCT00529984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX701
Description: 4 doses of AVX701 at 4e7 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX701
Description: 4 doses of AVX701 at 1e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX701
Description: 4 doses of AVX701 at 4e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX701
Description: 4 doses of AVX701 given at the maximally tolerated dose at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
Study: NCT03095209

Intervention type: DRUG
Intervention: Carboplatin
Description: chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
Study: NCT04108156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Description: Will be administered as per the schedule described in individual arm.
Study: NCT00529984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX701
Description: 4 Doses of AVX701 given to Stage III colon cancer subjects at the maximally tolerated dose at T=0, 3, 6, 9 weeks. There will be no option for subjects to receive additional immunizations.
Study: NCT01796756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handover program
Study: NCT00752102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol (Rocaltrol®)
Description: Subjects taking calcitriol will be started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then calcitriol will be increased to 0.5 mcg 3x/week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then paricalcitol will be increased to 4 mcg 3x/week.
Study: NCT01297075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach visits
Description: The 16 facilitators in the project attend an educational programme designed to provide them with the necessary skills and tools for the task. The facilitators visit general practice clinics from March 2011 until the end of 2012. Each clinic is offered three visits. The facilitator is to act as a change agent who motivates and helps the clinic team in the process of defining common goals, and choosing the appropriate means for achieving them.
Study: NCT01978418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: Medication given once as a dose of 4 puffs at 30-60 minutes of age

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given once as a dose of four puffs at 30-60 minutes of age
Study: NCT02056639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioteque cup pessary
Study: NCT03285672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-101
Description: Dose 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Dose 1
Study: NCT03945695

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic Vitreolysis in combination with Drinking-Bird-Technique
Description: 1. Appropriate anesthesia and antiseptic preparation of the surgical field~2. Prophylactic paracentesis of the anterior chamber~3. One intravitreal injection of 0.2 to 0.3 ml of filtered sulfur hexafluoride gas (SF6) into the test eye Remark: Intraocular pressure of the examined eye is to be controlled before the intervention and kept at an appropriate level after paracentesis by manual application of pressure.~4. Patients are instructed to avoid supine position and to lie on one side or the abdomen during sleep until complete resorption of intraocular gas occured. In this period they should bend over several times during the day up to an angle of 90º or as much as possible, resembling the movement of a bird drinking water. (Hence the name drinking-bird-technique.)
Study: NCT02673593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS102
Study: NCT04108156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Description: Will be administered as per the schedule described in individual arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Ranibizumab 0.5 mg Injection
Description: Will be administered as per the schedule described in individual arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab refill exchange
Description: Will be administered as per the schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab refill exchange
Description: Will be administered as per the schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab refill exchange
Description: Will be administered as per the schedule described in individual arm.
Study: NCT01136031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and irinotecan
Description: In phase I part, Level Paclitaxel (mg/m²) Irinotecan (mg/m²)~1. 100 100~2. 100 120~3. 135 120~4. 135 160~every 3 week
Study: NCT01801826

Intervention type: DEVICE
Intervention: Treatment with CryoTouch IV
Description: Bilateral forehead treatment with the Cryo-Touch IV device on the temporal branch of the facial nerve. Subject will be treated once and may have a retreatment up to 7 days after the first treatment
Study: NCT02606084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.
Study: NCT01209507

Intervention type: OTHER
Intervention: Chemotherapy
Description: This study is designed only to look at the prevalence of adrenal suppression during chemotherapy. If adrenal suppression is detected, treatment will be off-study at the treating physician's discretion.

Intervention type: OTHER
Intervention: Chemotherapy
Description: This study is designed only to look at the prevalence of adrenal suppression during chemotherapy. If adrenal suppression is detected, treatment will be off-study at the treating physician's discretion.
Study: NCT00864721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent
Description: Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
Study: NCT01669499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone acetate
Study: NCT02673593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS102
Study: NCT01669499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01636531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gantenerumab
Description: High concentration liquid formulation (HCLF), single dose sc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gantenerumab
Description: Lyophilized formulation (LyoF), single dose sc
Study: NCT04743466

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Biobank records are reviewed
Study: NCT01001013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC15-0444, Pioglitazone
Description: LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC15-0444, Pioglitazone
Description: LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC15-0444, Pioglitazone
Description: LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)
Study: NCT01499758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 Mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 80 Mg tablets
Study: NCT03731845

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sample for genetic test
Description: Patients will be genotyped for single nucleotide polymorphism previously found to be associated with age at natural menopause

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample for hormonal measurement
Description: at each visit : 2x7ml. At the end of the study hormonal measurements (AMH, P4, LH, FSH, E25)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ovarian ultrasound scan
Description: Ovarian ultrasound scan at follow up visits (Y1,Y1.5, Y2.5 Y3.5 Y4.5 Y5.5)
Study: NCT04042181

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: standard food grade excipients

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium longum
Description: Target dose of 1x10\^10 CFU/day, plus standard food grade excipients
Study: NCT03095209

Intervention type: DRUG
Intervention: Paclitaxel
Description: chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.

Intervention type: RADIATION
Intervention: Radiation Therapy
Description: The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer.
Study: NCT02616367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine Periarticular injection
Description: Liposomal bupivacaine used for a periarticular injection in the knee
Study: NCT04108156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab refill exchange
Description: Will be administered as per the schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab refill exchange
Description: Will be administered as per the schedule described in individual arm.
Study: NCT03164993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death ligand-1), which is expressed on tumour cells and tumour-infiltrating immune cells. PD-L1 interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, Atezolizumab may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: Chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Chemotherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05719246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga video set that the participants will follow is a brief, at-home, 6-week twice per week Standardized Yoga \& Meditation Program for Stress Reduction (SYMPro-SR) program. The videos feature Sydney Topfer guiding the participants through different yoga poses.
Study: NCT02655978

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Study: NCT02616367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Periarticular Injection
Description: Periarticular Injection for the knee with ropivacaine
Study: NCT02214108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii
Description: Tennis, box and bowling on Nintendo Wii, 3 hours per week.
Study: NCT04912362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YAG iridotomy
Description: YAG iridotomy was performed one week before operation, and then CO2 Laser-Assisted Sclerectomy Surgery was performed
Study: NCT02552277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDA-002
Description: PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDA-002
Description: PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo administered on study days 1, 29, and 57.
Study: NCT01270789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide administered as once daily sc injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered as once daily sc injection
Study: NCT01776528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282
Study: NCT01051882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-NTF cells transplantation (IM)
Description: In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells
Study: NCT01051882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-NTF cells transplantation (IT)
Description: In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.
Study: NCT02673593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00186745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Description: Dose: 175 IU/kg subcutaneously once daily, up to 7 days. Dose reduction as per protocol if anti-Xa levels exceed pre-defined limits.
Study: NCT01184404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
Study: NCT02481336

Intervention type: OTHER
Intervention: Questionnaires
Description: EORTC CIPN20 and EQ-5D-3L
Study: NCT01776528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02655978

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Study: NCT02194855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: Rocuronium 0.6 mg.kg-1 was administered within 5 s as an intravenous bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: Rocuronium 0.6 mg.kg-1 was administered within 5 s as an intravenous bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium
Description: cisatracurium 0.15mg.kg-1 was administered within 5 s as an intravenous bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium
Description: cisatracurium 0.15mg.kg-1 was administered within 5 s as an intravenous bolus
Study: NCT02481336

Intervention type: PROCEDURE
Intervention: Peripheral nervous system examination
Description: nerve conduction velocity (NCV), quantitative sensory test (QST), and nerve excitability test (NET)

Intervention type: GENETIC
Intervention: Whole Genome Sequence
Description: Genetic Test : 10 mL blood will be collected in Blood Sample Collection
Study: NCT02325674

Intervention type: DRUG
Intervention: Metreleptin
Study: NCT03766399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single dose of placebo for AZD0449 (nebulizer suspension).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single dose of placebo for AZD0449 (nebulizer suspension).
Study: NCT00878787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Study: NCT02010996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vacuum assisted closure
Description: Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary dissection
Description: Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
Study: NCT04351347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: ivermectin
Study: NCT00202839

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program followed by 1.2 to 1.5 microgram/kg weekly for 24 weeks during the extended treatment program

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program and for 24 weeks during the extended treatment program